Publication:
Statins in Non-alcoholic Steatohepatitis

Simple item page
dc.contributor.authorTorres-Peña, Jose D.
dc.contributor.authorMartín-Piedra, Laura
dc.contributor.authorFuentes-Jiménez, Francisco
dc.contributor.authoraffiliation[Torres-Peña,JD; Martín-Piedra,L; Fuentes-Jiménez,F] Lipids and Atherosclerosis Unit, Department of Internal Medicine, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Córdoba, Córdoba, Spain. [Torres-Peña,JD; Martín-Piedra,L; Fuentes-Jiménez,F] CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Córdoba, Spain.
dc.date.accessioned2022-11-08T07:42:20Z
dc.date.available2022-11-08T07:42:20Z
dc.date.issued2021-11-24
dc.description.abstractNon-alcoholic fatty liver disease (NAFLD) is the primary cause of chronic liver disease. The range is extensive, including hepatocellular carcinoma, cirrhosis, fibrosis, fatty liver, and non-alcoholic steatohepatitis (NASH). NASH is a condition related to obesity, overweight, metabolic syndrome, diabetes, and dyslipidemia. It is a dynamic condition that can regress to isolated steatosis or progress to fibrosis and cirrhosis. Statins exert anti-inflammatory, proapoptotic, and antifibrotic effects. It has been proposed that these drugs could have a relevant role in NASH. In this review, we provide an overview of current evidence, from mechanisms of statins involved in the modulation of NASH to human trials about the use of statins to treat or attenuate NASH.es_ES
dc.description.versionYeses_ES
dc.identifier.citationTorres-Peña JD, Martín-Piedra L, Fuentes-Jiménez F. Statins in Non-alcoholic Steatohepatitis. Front Cardiovasc Med. 2021 Nov 24;8:777131es_ES
dc.identifier.doi10.3389/fcvm.2021.777131es_ES
dc.identifier.essn2297-055X
dc.identifier.pmcPMC8652077
dc.identifier.pmid34901236es_ES
dc.identifier.urihttp://hdl.handle.net/10668/4342
dc.journal.titleFrontiers in Cardiovascular Medicine
dc.language.isoen
dc.page.number9 p.
dc.publisherFrontierses_ES
dc.relation.publisherversionhttps://www.frontiersin.org/articles/10.3389/fcvm.2021.777131/fulles_ES
dc.rightsAtribución 4.0 Internacional*
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectStatinses_ES
dc.subjectNASHes_ES
dc.subjectCardiovascular diseasees_ES
dc.subjectLiveres_ES
dc.subjectAminotransferasees_ES
dc.subjectHepatocellular carcinomaes_ES
dc.subjectMetabolic syndromees_ES
dc.subjectCirrhosises_ES
dc.subjectDyslipidemiaes_ES
dc.subjectObesityes_ES
dc.subjectAnti-inflammatoryes_ES
dc.subjectDiabeteses_ES
dc.subjectInhibidores de hidroximetilglutaril-CoA reductasases_ES
dc.subjectEnfermedad del hígado graso no alcohólicoes_ES
dc.subjectEnfermedades cardiovasculareses_ES
dc.subjectHígadoes_ES
dc.subjectTransaminasases_ES
dc.subjectCarcinoma hepatocelulares_ES
dc.subjectSíndrome metabólicoes_ES
dc.subjectCirrosises_ES
dc.subjectFibrosises_ES
dc.subjectCirrosis hepáticaes_ES
dc.subjectDislipidemiases_ES
dc.subjectObesidades_ES
dc.subjectAntiinflamatorioses_ES
dc.subject.meshMedical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humanses_ES
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Antimetabolites::Hypolipidemic Agents::Anticholesteremic Agents::Hydroxymethylglutaryl-CoA Reductase Inhibitorses_ES
dc.subject.meshMedical Subject Headings::Diseases::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Glandular and Epithelial::Carcinoma::Adenocarcinoma::Carcinoma, Hepatocellulares_ES
dc.subject.meshMedical Subject Headings::Diseases::Nutritional and Metabolic Diseases::Metabolic Diseases::Metabolic Syndrome Xes_ES
dc.subject.meshMedical Subject Headings::Diseases::Pathological Conditions, Signs and Symptoms::Signs and Symptoms::Body Weight::Overweightes_ES
dc.subject.meshMedical Subject Headings::Diseases::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Liver Neoplasmses_ES
dc.subject.meshMedical Subject Headings::Diseases::Digestive System Diseases::Liver Diseases::Liver Cirrhosises_ES
dc.subject.meshMedical Subject Headings::Diseases::Nutritional and Metabolic Diseases::Metabolic Diseases::Lipid Metabolism Disorders::Dyslipidemiases_ES
dc.subject.meshMedical Subject Headings::Diseases::Nutritional and Metabolic Diseases::Nutrition Disorders::Overnutrition::Obesityes_ES
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Inflammatory Agentses_ES
dc.subject.meshMedical Subject Headings::Diseases::Endocrine System Diseases::Diabetes Mellituses_ES
dc.subject.meshMedical Subject Headings::Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Fibrosises_ES
dc.titleStatins in Non-alcoholic Steatohepatitises_ES
dc.typereview article
dc.type.hasVersionVoR
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
TorresPeña_StatinsIn.pdf
Size:
906.96 KB
Format:
Adobe Portable Document Format
Description:
Revisión
Download

Collections

Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)
SAS - Hospital Universitario Reina Sofía

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía